• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cerebrovascular Disease - Pipeline Review, H2 2012 Product Image

Cerebrovascular Disease - Pipeline Review, H2 2012

  • Published: October 2012
  • 391 pages
  • Global Markets Direct

Cerebrovascular Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cerebrovascular Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cerebrovascular Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cerebrovascular Disease. Cerebrovascular Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cerebrovascular Disease.
- A review of the Cerebrovascular Disease products under development READ MORE >

2
List of Tables 18
List of Figures 21
Introduction 22
REPORT COVERAGE 22
Cerebrovascular Disease Overview 23
Therapeutics Development 24
An Overview of Pipeline Products for Cerebrovascular Disease 24
Cerebrovascular Disease Therapeutics under Development by Companies 26
Cerebrovascular Disease Therapeutics under Investigation by Universities/Institutes 33
Late Stage Products 38
Comparative Analysis 38
Mid Clinical Stage Products 39
Comparative Analysis 39
Early Clinical Stage Products 40
Comparative Analysis 40
Discovery and Pre-Clinical Stage Products 41
Comparative Analysis 41
Cerebrovascular Disease Therapeutics – Products under Development by Companies 42
Cerebrovascular Disease Therapeutics – Products under Investigation by Universities/Institutes 48
Companies Involved in Cerebrovascular Disease Therapeutics Development 52
Bristol-Myers Squibb Company 52
Johnson & Johnson 53
NsGene A/S 54
Amgen Inc. 55
Sanofi-Aventis 56
Athersys, Inc. 57
GlaxoSmithKline plc 58
Daiichi Sankyo Company, Ltd 59
Merck & Co., Inc. 60
Sangamo BioSciences, Inc. 61
CardioVascular BioTherapeutics, Inc. 62
Aldagen, Inc. 63
Acorda Therapeutics, Inc. 64
Glenmark Pharmaceuticals Ltd. 65
H Lundbeck A/S 66
Jeil Pharmaceutical Co., Ltd. 67
Mitsubishi Tanabe Pharma Corporation 68
Pfizer Inc. 69
Celgene Corporation 70
Anavex Life Sciences Corp. 71
Proneuron Biotechnologies, Inc. 72
Neuralstem, Inc. 73
Living Cell Technologies Limited 74
Neuren Pharmaceuticals Limited 75
Cortex Pharmaceuticals, Inc. 76
KOLON LIFE SCIENCE INC. 77
WhanIn Pharmaceutical Co., Ltd. 78
RegeneRx Biopharmaceuticals, Inc. 79
POZEN Inc. 80
ReNeuron Group plc 81
Dongwha Pharm Co., Ltd. 82
Pluristem Therapeutics Inc. 83
MediPost Co., Ltd. 84
Simcere Pharmaceutical Group 85
Stem Cell Therapeutics Corp. 86
NeuroVive Pharmaceutical AB 87
D-Pharm Ltd. 88
StemCells, Inc. 89
SCYNEXIS, Inc. 90
KeyNeurotek Pharmaceuticals AG 91
Pharmagenesis, Inc. 92
BioMAS Ltd. 93
Artielle ImmunoTherapeutics, Inc. 94
Endotis Pharma 95
Regado Biosciences. 96
Remedy Pharmaceuticals, Inc. 97
Fina Biotech 98
Angion Biomedica Corp. 99
Palkion, Inc. 100
Stemedica Cell Technologies, Inc. 101
SanBio, Inc. 102
KYORIN Pharmaceutical Co., Ltd. 103
Diakron Pharmaceuticals, Inc. 104
Lacer, S.A. 105
M's Science Corporation 106
Sihuan Pharmaceutical Holdings Group Ltd. 107
Thrombotech Technologies, Ltd. 108
Gaia BioPharma Limited 109
ArmaGen Technologies, Inc. 110
Sinapis Pharma, Inc 111
RNL BIO Co., Ltd. 112
Cellmid Ltd 113
InVasc Therapeutics, Inc. 114
Stempeutics Research Private Limited 115
Ampio Pharmaceuticals, Inc. 116
Cerebrovascular Disease – Therapeutics Assessment 117
Assessment by Monotherapy Products 117
Assessment by Combination Products 118
Assessment by Route of Administration 119
Assessment by Molecule Type 122
Drug Profiles 125
GSK-249320 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
MP-124 - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
PA-08140 - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
DP-b99 - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
DP-b99 - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
GAI-122 - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
KN38-7271 - Drug Profile 174
Product Description 174
Mechanism of Action 174
R&D Progress 174
AGT-190 - Drug Profile 175
Product Description 175
Mechanism of Action 175
R&D Progress 175
SB-623 - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
SA-4503 - Drug Profile 178
Product Description 178
Mechanism of Action 178
R&D Progress 178
PG-2 - Drug Profile 180
Product Description 180
Mechanism of Action 180
R&D Progress 180
lisinopril - Drug Profile 182
Product Description 182
Mechanism of Action 182
R&D Progress 182
NNZ-2591 - Drug Profile 183
Product Description 183
Mechanism of Action 183
R&D Progress 183
minocycline - Drug Profile 185
Product Description 185
Mechanism of Action 185
R&D Progress 185
donepezil hydrochloride - Drug Profile 194
Product Description 194
Mechanism of Action 194
R&D Progress 194
AS-101 - Drug Profile 195
Product Description 195
Mechanism of Action 195
R&D Progress 195
NA-1 - Drug Profile 197
Product Description 197
Mechanism of Action 197
R&D Progress 197
Polypill - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 199
SAR-126119 - Drug Profile 249
Product Description 249
Mechanism of Action 249
R&D Progress 249
NSI-189 - Drug Profile 250
Product Description 250
Mechanism of Action 250
R&D Progress 250
INV-155 - Drug Profile 252
Product Description 252
Mechanism of Action 252
R&D Progress 252
ReN-001 - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
PLX–STROKE - Drug Profile 254
Product Description 254
Mechanism of Action 254
R&D Progress 254
Autologous Bone-Marrow Mononuclear Cells - Drug Profile 275
Product Description 275
Mechanism of Action 275
R&D Progress 275
PARP-1 Inhibitor - Drug Profile 276
Product Description 276
Mechanism of Action 276
R&D Progress 276
Netrin-1 - Drug Profile 277
Product Description 277
Mechanism of Action 277
R&D Progress 277
Cell Therapy For Stroke - Drug Profile 278
Product Description 278
Mechanism of Action 278
R&D Progress 278
DMI-4983 - Drug Profile 279
Product Description 279
Mechanism of Action 279
R&D Progress 279
Cyclophilin Inhibitory Compounds - Drug Profile 315
Product Description 315
Mechanism of Action 315
R&D Progress 315
Allogenic Mesenchymal Stem Cells From Adipose Tissue - Drug Profile 316
Product Description 316
Mechanism of Action 316
R&D Progress 316
Umbilical Cord Blood CD34+ Stem Cell - Drug Profile 317
Product Description 317
Mechanism of Action 317
R&D Progress 317
Cerebrovascular Disease Therapeutics – Drug Profile Updates 318
Cerebrovascular Disease Therapeutics – Discontinued Products 371
Cerebrovascular Disease Therapeutics - Dormant Products 375
Cerebrovascular Disease – Product Development Milestones 382
Featured News & Press Releases 382
Oct 02, 2012: Athersys Reports On Progress In Phase II Study Of MultiStem For Ischemic Stroke 382
Oct 01, 2012: Bristol-Myers Squibb And Pfizer Announce Eliquis Demonstrates Better Results Than Warfarin In Patients With Atrial Fibrillation At Varying Risk For Stroke And Bleeding 382
Sep 27, 2012: Neuralstem Receives Approval To Commence Ischemic Stroke Trial In China 384
Sep 26, 2012: Bristol-Myers Squibb And Pfizer Announce FDA Acknowledges Receipt Of Resubmission Of Eliquis NDA And Grants New PDUFA Date 384
Sep 25, 2012: NICE Recommends Boehringer Ingelheim's Alteplase For Treatment Of Acute Ischemic Stroke 385
Sep 21, 2012: Bristol-Myers Squibb And Pfizer Receive CHMP Positive Opinion For Eliquis For Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation 386
Sep 12, 2012: Boehringer Ingelheim Announces Asian Populations With Atrial fibrillation Benefit From Better Stroke Prevention With Pradaxa Compared To Warfarin 386
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN001 In UK 387
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN009 In UK 388
Aug 26, 2012: Merck Provides Update On Vorapaxar Development Program 389
Appendix 390
Methodology 390
Coverage 390
Secondary Research 390
Primary Research 390
Expert Panel Validation 390
Contact Us 391
Disclaimer 391

List of Tables
Number of Products Under Development for Cerebrovascular Disease, H2 2012 24
Products under Development for Cerebrovascular Disease – Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Development by Companies, H2 2012 (Contd..2) 29
Number of Products under Development by Companies, H2 2012 (Contd..3) 30
Number of Products under Development by Companies, H2 2012 (Contd..4) 31
Number of Products under Development by Companies, H2 2012 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Investigation by Universities/Institutes, H2 2012 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 51
Bristol-Myers Squibb Company, H2 2012 52
Johnson & Johnson, H2 2012 53
NsGene A/S, H2 2012 54
Amgen Inc., H2 2012 55
Sanofi-Aventis, H2 2012 56
Athersys, Inc., H2 2012 57
GlaxoSmithKline plc, H2 2012 58
Daiichi Sankyo Company, Ltd, H2 2012 59
Merck & Co., Inc., H2 2012 60
Sangamo BioSciences, Inc., H2 2012 61
CardioVascular BioTherapeutics, Inc., H2 2012 62
Aldagen, Inc., H2 2012 63
Acorda Therapeutics, Inc., H2 2012 64
Glenmark Pharmaceuticals Ltd., H2 2012 65
H Lundbeck A/S, H2 2012 66
Jeil Pharmaceutical Co., Ltd., H2 2012 67
Mitsubishi Tanabe Pharma Corporation, H2 2012 68
Pfizer Inc., H2 2012 69
Celgene Corporation, H2 2012 70
Anavex Life Sciences Corp., H2 2012 71
Proneuron Biotechnologies, Inc., H2 2012 72
Neuralstem, Inc., H2 2012 73
Living Cell Technologies Limited, H2 2012 74
Neuren Pharmaceuticals Limited, H2 2012 75
Cortex Pharmaceuticals, Inc., H2 2012 76
KOLON LIFE SCIENCE INC., H2 2012 77
WhanIn Pharmaceutical Co., Ltd., H2 2012 78
RegeneRx Biopharmaceuticals, Inc., H2 2012 79
POZEN Inc., H2 2012 80
ReNeuron Group plc, H2 2012 81
Dongwha Pharm Co., Ltd., H2 2012 82
Pluristem Therapeutics Inc., H2 2012 83
MediPost Co., Ltd., H2 2012 84
Simcere Pharmaceutical Group, H2 2012 85
Stem Cell Therapeutics Corp., H2 2012 86
NeuroVive Pharmaceutical AB, H2 2012 87
D-Pharm Ltd., H2 2012 88
StemCells, Inc., H2 2012 89
SCYNEXIS, Inc., H2 2012 90
KeyNeurotek Pharmaceuticals AG, H2 2012 91
Pharmagenesis, Inc., H2 2012 92
BioMAS Ltd., H2 2012 93
Artielle ImmunoTherapeutics, Inc., H2 2012 94
Endotis Pharma, H2 2012 95
Regado Biosciences., H2 2012 96
Remedy Pharmaceuticals, Inc., H2 2012 97
Fina Biotech, H2 2012 98
Angion Biomedica Corp., H2 2012 99
Palkion, Inc., H2 2012 100
Stemedica Cell Technologies, Inc., H2 2012 101
SanBio, Inc., H2 2012 102
KYORIN Pharmaceutical Co., Ltd., H2 2012 103
Diakron Pharmaceuticals, Inc., H2 2012 104
Lacer, S.A., H2 2012 105
M's Science Corporation, H2 2012 106
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 107
Thrombotech Technologies, Ltd., H2 2012 108
Gaia BioPharma Limited, H2 2012 109
ArmaGen Technologies, Inc., H2 2012 110
Sinapis Pharma, Inc, H2 2012 111
RNL BIO Co., Ltd., H2 2012 112
Cellmid Ltd, H2 2012 113
InVasc Therapeutics, Inc., H2 2012 114
Stempeutics Research Private Limited, H2 2012 115
Ampio Pharmaceuticals, Inc., H2 2012 116
Assessment by Monotherapy Products, H2 2012 117
Assessment by Combination Products, H2 2012 118
Assessment by Stage and Route of Administration, H2 2012 121
Assessment by Stage and Molecule Type, H2 2012 124
Cerebrovascular Disease Therapeutics – Drug Profile Updates 318
Cerebrovascular Disease Therapeutics – Discontinued Products 371
Cerebrovascular Disease Therapeutics – Discontinued Products (Contd..1) 372
Cerebrovascular Disease Therapeutics – Discontinued Products (Contd..2) 373
Cerebrovascular Disease Therapeutics – Discontinued Products (Contd..3) 374
Cerebrovascular Disease Therapeutics – Dormant Products 375
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..1) 376
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..2) 377
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..3) 378
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..4) 379
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..5) 380
Cerebrovascular Disease Therapeutics – Dormant Products (Contd..6) 381

List of Figures
Number of Products under Development for Cerebrovascular Disease, H2 2012 24
Products under Development for Cerebrovascular Disease – Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 33
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 117
Assessment by Combination Products, H2 2012 118
Assessment by Route of Administration, H2 2012 119
Assessment by Stage and Route of Administration, H2 2012 120
Assessment by Molecule Type, H2 2012 122
Assessment by Stage and Molecule Type, H2 2012 123

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos